Clinical trial

Asiaticoside for Treating Overweight/Obesity

Recruiting now · Not applicable · 1 countries · Registry ID NCT07241533

Recruiting nowNot applicableInterventional

What this study is about

Centella asiatica is a traditional herbal medicine widely used in China and Southeast Asia for treating various conditions. Preclinical studies have shown that madecassic acid glycosides, including asiaticoside and madecassoside, can significantly reduce body weight gain, adipose tissue mass, and serum triglyceride levels in high-fat diet-induced obese mice. These compounds also improve hepatic steatosis and insulin resistance. This exploratory, interventional study aims to evaluate the clinical efficacy of orally administered asiaticoside tablets in adults with overweight or obesity.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersNot accepted

ConditionOverweight , Obesity

Full registry criteria

Inclusion Criteria: * Adults aged 18 years or older, male or female. * Overweight or obesity, defined as a body mass index (BMI) of 24.0-45.0 kg/m². * Able and willing to provide written informed consent. Exclusion Criteria: * Active pulmonary tuberculosis, malignant tumors, human immunodeficiency virus (HIV) infection, or other severe infectious or immunocompromising conditions. * Severe liver injury (AST or ALT \> 3 times the upper limit of normal) or severe renal dysfunction/end-stage renal disease (eGFR \< 30 mL/min/1.73 m²). * Severe cardiovascular diseases, including angina pectoris, myocardial infarction, or stroke within the past 6 months. * Severe gastrointestinal disorders, or a history of gastrointestinal surgery within the past year. * Secondary causes of obesity, including Cushing's syndrome, primary hypothyroidism, hypothalamic obesity, acromegaly; or drug-induced obesity (e.g., antipsychotics, glucocorticoids). * Currently receiving other anti-obesity treatments, a previous history of bariatric surgery, or a \>5% reduction in body weight within the past 3 months. * Current smoker or habitual smoker within the past 3 months. * type 1 or type 2 diabetes mellitus or currently taking hypoglycemic medications. * Pregnancy or planning pregnancy, or breastfeeding. * Unable to complete a 3-month follow-up due to health conditions or relocation. * Participation in any clinical study within the past 4 weeks. * Other conditions considered by investigators as unsuitable for participation.

Treatments and study arms

Asiaticoside tablets

Drug

Asiaticoside tablets 60mg tid for 12 weeks

Primary outcomes

Change in Metabolic RateBaseline to Week 4

Metabolic rate will be assessed using indirect calorimetry in a metabolic chamber (whole-room indirect calorimetry) at baseline and Week 4 after taking Asiaticoside tablets.

Change in Body WeightBaseline to Week 12

Body weight will be measured using a calibrated digital scale at baseline and Week 12 after taking Asiaticoside tablets.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Zhongshan Hospital, Fudan University🇨🇳 Shanghai, Shanghai Municipality, China

Open map

JINGJING JIANG, MD, PhDContact

Email · Call 86-21-64041990

HUIJIE ZHANG, MD, PhDPrincipal Investigator